Mol Microbiol:揭秘耐药菌毒力因子的特殊结构单元或可开发新型抗生素

2015-05-12 佚名 生物谷

近日,一项发表于国际杂志Molecular Microbiology上的研究论文中,来自阿德莱德大学的科学家通过研究发现了一种新型靶点,该靶点或为开发抵御引发疾病细菌的新型抗生素提供一定的帮助;文章中研究者鉴别出了对许多细菌毒力因子较为常见的结构单元,细菌的毒力因子是一种可以引发疾病的特殊蛋白质,比如毒素类或降解酶。 这种结构单元名为“旅客”相关的运输重复结构(PATR,Passenger-

近日,一项发表于国际杂志Molecular Microbiology上的研究论文中,来自阿德莱德大学的科学家通过研究发现了一种新型靶点,该靶点或为开发抵御引发疾病细菌的新型抗生素提供一定的帮助;文章中研究者鉴别出了对许多细菌毒力因子较为常见的结构单元,细菌的毒力因子是一种可以引发疾病的特殊蛋白质,比如毒素类或降解酶。

这种结构单元名为“旅客”相关的运输重复结构(PATR,Passenger-associated Transport Repeat),这种结构是在许多有害细菌的毒力因子中发现的,比如沙门氏菌、志贺氏菌、脑膜炎球菌以及一些引发囊性纤维化的细菌;而且这种结构在很多革兰氏阴性菌中都存在,其中就包括一些对很多抗生素产生耐药性的细菌。

PATR在细菌毒力因子运输至细胞表面的过程可以表现出较为完整的结构以便其作为致病因子发挥作用;研究者Matthew Doyle说道,当细菌毒力因子被适当产生并且被分泌到细胞表面时其就会引发疾病,我们的研究非常激动人心,我们不仅发现了存在于特殊病原体中的关键毒力分子,而且还发现了许多致病菌毒力常见毒力因子所共有的毒力结构单元,这就为后期开发广谱抑制细菌毒力的抑制剂提供了一定的帮助。

本文研究也可以用于生物技术领域来进行市场化产品的开发,研究者表示,这种毒力因子的特殊结构单元通常都会被忽略,而其对于后期进行耐药性细菌疗法的开发或许会带来巨大的帮助。

原始出处:

Matthew Thomas Doyle, Elizabeth Ngoc Hoa Tran andRenato Morona*.The passenger-associated transport repeat promotes virulence factor secretion efficiency and delineates a distinct autotransporter subtype.Molecular microbiology, May 9, 2015.DOI:10.1111/MMI.13027

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1857347, encodeId=8a60185e34743, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Fri Dec 18 10:04:00 CST 2015, time=2015-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084122, encodeId=533f208412205, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Mar 21 03:04:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917155, encodeId=c6cd191e155d4, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Aug 13 01:04:00 CST 2015, time=2015-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1676850, encodeId=407116e6850fe, content=<a href='/topic/show?id=63825823146' target=_blank style='color:#2F92EE;'>#新型抗生素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58231, encryptionId=63825823146, topicName=新型抗生素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bab27396846, createdName=marongnuan, createdTime=Tue Nov 03 18:04:00 CST 2015, time=2015-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766943, encodeId=429f1e6694304, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Fri Jul 10 22:04:00 CST 2015, time=2015-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418653, encodeId=66411418653d6, content=<a href='/topic/show?id=b07e8041efb' target=_blank style='color:#2F92EE;'>#耐药菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80417, encryptionId=b07e8041efb, topicName=耐药菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10723392161, createdName=xiaoshitou, createdTime=Thu May 14 00:04:00 CST 2015, time=2015-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23384, encodeId=d3142338461, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed May 13 21:01:00 CST 2015, time=2015-05-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1857347, encodeId=8a60185e34743, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Fri Dec 18 10:04:00 CST 2015, time=2015-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084122, encodeId=533f208412205, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Mar 21 03:04:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917155, encodeId=c6cd191e155d4, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Aug 13 01:04:00 CST 2015, time=2015-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1676850, encodeId=407116e6850fe, content=<a href='/topic/show?id=63825823146' target=_blank style='color:#2F92EE;'>#新型抗生素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58231, encryptionId=63825823146, topicName=新型抗生素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bab27396846, createdName=marongnuan, createdTime=Tue Nov 03 18:04:00 CST 2015, time=2015-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766943, encodeId=429f1e6694304, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Fri Jul 10 22:04:00 CST 2015, time=2015-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418653, encodeId=66411418653d6, content=<a href='/topic/show?id=b07e8041efb' target=_blank style='color:#2F92EE;'>#耐药菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80417, encryptionId=b07e8041efb, topicName=耐药菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10723392161, createdName=xiaoshitou, createdTime=Thu May 14 00:04:00 CST 2015, time=2015-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23384, encodeId=d3142338461, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed May 13 21:01:00 CST 2015, time=2015-05-13, status=1, ipAttribution=)]
    2016-03-21 xjy02
  3. [GetPortalCommentsPageByObjectIdResponse(id=1857347, encodeId=8a60185e34743, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Fri Dec 18 10:04:00 CST 2015, time=2015-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084122, encodeId=533f208412205, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Mar 21 03:04:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917155, encodeId=c6cd191e155d4, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Aug 13 01:04:00 CST 2015, time=2015-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1676850, encodeId=407116e6850fe, content=<a href='/topic/show?id=63825823146' target=_blank style='color:#2F92EE;'>#新型抗生素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58231, encryptionId=63825823146, topicName=新型抗生素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bab27396846, createdName=marongnuan, createdTime=Tue Nov 03 18:04:00 CST 2015, time=2015-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766943, encodeId=429f1e6694304, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Fri Jul 10 22:04:00 CST 2015, time=2015-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418653, encodeId=66411418653d6, content=<a href='/topic/show?id=b07e8041efb' target=_blank style='color:#2F92EE;'>#耐药菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80417, encryptionId=b07e8041efb, topicName=耐药菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10723392161, createdName=xiaoshitou, createdTime=Thu May 14 00:04:00 CST 2015, time=2015-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23384, encodeId=d3142338461, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed May 13 21:01:00 CST 2015, time=2015-05-13, status=1, ipAttribution=)]
    2015-08-13 sunylz
  4. [GetPortalCommentsPageByObjectIdResponse(id=1857347, encodeId=8a60185e34743, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Fri Dec 18 10:04:00 CST 2015, time=2015-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084122, encodeId=533f208412205, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Mar 21 03:04:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917155, encodeId=c6cd191e155d4, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Aug 13 01:04:00 CST 2015, time=2015-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1676850, encodeId=407116e6850fe, content=<a href='/topic/show?id=63825823146' target=_blank style='color:#2F92EE;'>#新型抗生素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58231, encryptionId=63825823146, topicName=新型抗生素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bab27396846, createdName=marongnuan, createdTime=Tue Nov 03 18:04:00 CST 2015, time=2015-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766943, encodeId=429f1e6694304, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Fri Jul 10 22:04:00 CST 2015, time=2015-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418653, encodeId=66411418653d6, content=<a href='/topic/show?id=b07e8041efb' target=_blank style='color:#2F92EE;'>#耐药菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80417, encryptionId=b07e8041efb, topicName=耐药菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10723392161, createdName=xiaoshitou, createdTime=Thu May 14 00:04:00 CST 2015, time=2015-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23384, encodeId=d3142338461, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed May 13 21:01:00 CST 2015, time=2015-05-13, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1857347, encodeId=8a60185e34743, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Fri Dec 18 10:04:00 CST 2015, time=2015-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084122, encodeId=533f208412205, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Mar 21 03:04:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917155, encodeId=c6cd191e155d4, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Aug 13 01:04:00 CST 2015, time=2015-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1676850, encodeId=407116e6850fe, content=<a href='/topic/show?id=63825823146' target=_blank style='color:#2F92EE;'>#新型抗生素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58231, encryptionId=63825823146, topicName=新型抗生素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bab27396846, createdName=marongnuan, createdTime=Tue Nov 03 18:04:00 CST 2015, time=2015-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766943, encodeId=429f1e6694304, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Fri Jul 10 22:04:00 CST 2015, time=2015-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418653, encodeId=66411418653d6, content=<a href='/topic/show?id=b07e8041efb' target=_blank style='color:#2F92EE;'>#耐药菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80417, encryptionId=b07e8041efb, topicName=耐药菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10723392161, createdName=xiaoshitou, createdTime=Thu May 14 00:04:00 CST 2015, time=2015-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23384, encodeId=d3142338461, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed May 13 21:01:00 CST 2015, time=2015-05-13, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1857347, encodeId=8a60185e34743, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Fri Dec 18 10:04:00 CST 2015, time=2015-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084122, encodeId=533f208412205, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Mar 21 03:04:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917155, encodeId=c6cd191e155d4, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Aug 13 01:04:00 CST 2015, time=2015-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1676850, encodeId=407116e6850fe, content=<a href='/topic/show?id=63825823146' target=_blank style='color:#2F92EE;'>#新型抗生素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58231, encryptionId=63825823146, topicName=新型抗生素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bab27396846, createdName=marongnuan, createdTime=Tue Nov 03 18:04:00 CST 2015, time=2015-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766943, encodeId=429f1e6694304, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Fri Jul 10 22:04:00 CST 2015, time=2015-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418653, encodeId=66411418653d6, content=<a href='/topic/show?id=b07e8041efb' target=_blank style='color:#2F92EE;'>#耐药菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80417, encryptionId=b07e8041efb, topicName=耐药菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10723392161, createdName=xiaoshitou, createdTime=Thu May 14 00:04:00 CST 2015, time=2015-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23384, encodeId=d3142338461, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed May 13 21:01:00 CST 2015, time=2015-05-13, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1857347, encodeId=8a60185e34743, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Fri Dec 18 10:04:00 CST 2015, time=2015-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084122, encodeId=533f208412205, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Mon Mar 21 03:04:00 CST 2016, time=2016-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917155, encodeId=c6cd191e155d4, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Aug 13 01:04:00 CST 2015, time=2015-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1676850, encodeId=407116e6850fe, content=<a href='/topic/show?id=63825823146' target=_blank style='color:#2F92EE;'>#新型抗生素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58231, encryptionId=63825823146, topicName=新型抗生素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bab27396846, createdName=marongnuan, createdTime=Tue Nov 03 18:04:00 CST 2015, time=2015-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766943, encodeId=429f1e6694304, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Fri Jul 10 22:04:00 CST 2015, time=2015-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418653, encodeId=66411418653d6, content=<a href='/topic/show?id=b07e8041efb' target=_blank style='color:#2F92EE;'>#耐药菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80417, encryptionId=b07e8041efb, topicName=耐药菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10723392161, createdName=xiaoshitou, createdTime=Thu May 14 00:04:00 CST 2015, time=2015-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23384, encodeId=d3142338461, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed May 13 21:01:00 CST 2015, time=2015-05-13, status=1, ipAttribution=)]
    2015-05-13 huaxipanxing

    看看

    0

相关资讯

美报告称耐药菌每年夺去2.3万人生命

实验室显微镜下的抗碳青霉烯肠杆菌,其对最强的抗菌素也有抵抗性。 据美国中文网9月16日报道,美国联邦官员发布16日报告,称全美每年有230万人感染抗药性病菌,其中2.3万人被“超级病菌”夺命。而这其中最大的杀手就是顽固性梭菌(C. difficile)。报告同时指出,医生几十年来都在警告不要滥用抗菌素,但全美超过一半抗菌素处方药都是不必要的,滥用抗菌素造成“超级病菌

PNAS:美开发预测超级细菌耐药突变的软件

随着耐药细菌的增加,即使是几十年来容易控制的常见感染——例如肺炎或尿路感染,用标准抗生素都难以治疗。因此迫切需要研制新的药物,同时也需要某种方法最大程度地发挥这些药物的有效使用寿命。 为了实现这一目标,美国杜克大学的研究人员使用他们开发的软件,提前预测不断变化的感染细菌如何对抗这些新药,甚至在患者身上测试这些药物之前都能进行预测。 12月31日在PNAS发表的一项研究中,该研究小组

CID:IDSA称抗生素发展缓慢 无力应对日益加剧的耐药菌

尽管对能够抵御致死性细菌的新抗生素需求十分迫切,然而,自2010年美国传染病学会(IDSA)发布“10 x '20 行动”(即至2020年,推出10个全新的抗生素)以来,至今只有1个合成的新抗生素被美国FDA批准,而这已经是两年半前的事情了。据《Clinical Infectious Diseases》的最新报道,IDSA表示,目前只有7个针对多重耐药GNB(革兰阴性杆菌)的在研抗生素。GNB种类

PNAS:新化合物能抗击耐药菌

  耶鲁大学科学家使用人类免疫系统中的物质开发出了一种能中和或杀灭多种耐药菌和其他危险菌的化合物,这为感染性疾病新的治疗方法带来了希望。相关研究于9月26日发表于《美国国家科学院院刊》(PNAS)。   诺贝尔奖得主、该研究高级研究作者、化学教授Sidney Altman说,“在当前药物中使用的浓度下该化合物是有效的,并有望用于抗击感染性疾病及耐药性生物。”1989年,Altman和Thomas

Lancet Infect Dis:干预措施可减少耐药菌在ICU的定植传播(MOSAR WP3研究)

ICU是耐药性细菌传播的高发地带,有一些干预措施已经得到公认。但是快速检测和隔离带菌者是否能有效的预防耐药菌的传播,仍缺乏相关的对照性研究。荷兰乌德勒支大学的研究人员联合欧洲多家医院的ICU医疗人员对此进行了研究。研究结果表明:必要干预措施可以减少对抗菌药物耐药的细菌在重症监护病房的定植和传播。该研究成果发表在2014年1月的《柳叶刀:感染性疾病》(Lancet Infect Dis)杂志上。